Updated:
Delcath Systems
Delcath Systems was founded in 1988 and is headquartered in New York. The company is led by CEO Gerard Michel.
Delcath Systems
Delcath Systems was founded in 1988 and is headquartered in New York. The company is led by CEO Gerard Michel. Delcath is a medical technology firm rather than an investment entity, and it does not operate a family office or manage external capital on behalf of a founder's wealth. The firm's activities are centered on the commercialization of the HEPZATO KIT, a drug-device combination product. The company received FDA approval for HEPZATO in August 2023, allowing targeted delivery of chemotherapy to the liver while minimizing systemic exposure. Delcath markets this system in the United States and Europe. Delcath's strategy is entirely operational, not investment-focused. The company deploys its capital into manufacturing, clinical education, and direct sales infrastructure to support the commercial launch of its hepatic delivery platform. In the second quarter of 2024, Delcath reported its first revenue from the U.S. commercial launch of HEPZATO. The firm focuses on interventional oncology, a specialized niche within the broader healthcare sector. Patients with metastatic uveal melanoma, the primary initial indication, represent a defined but underserved market. Team scale is modest. Delcath is a micro-cap company with a lean commercial organization structured to support a single approved product. The firm operates from its headquarters in New York. There are no adjacent family-office vehicles, co-investment clubs, or philanthropic foundations tied to a wealth-origin story here. In September 2024, Delcath announced an expansion of HEPZATO's clinical development program into additional liver-dominant tumor types, signaling a broader pipeline strategy for the platform. Delcath's structural differentiator is its nature as an operating company rather than any form of asset manager. It does not accept outside capital for investment purposes; its capital comes from equity financings in the public market. The entity's architecture is defined by its FDA-approved device monopoly position and a patent-protected technology platform.
General information
Firm type
Asset Manager
Year founded
1988
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Gerard Michel
Chief Executive Officer
Sector focus
Frequently asked questions
Is Delcath Systems a family office or an investment manager?
No. Delcath Systems is a commercial-stage medical technology company publicly traded on the Nasdaq. It does not manage third-party capital, operate as a family office, or make fund commitments. The firm sells a medical device to hospitals.
What does Delcath Systems actually do?
Delcath manufactures and sells the HEPZATO KIT, a drug-device combination approved by the FDA for the treatment of adult patients with metastatic uveal melanoma with unresectable liver metastases. The system isolates the liver's blood supply to deliver a high dose of chemotherapy directly to the organ, then filters the blood before it returns to the rest of the body.
Who runs Delcath Systems?
Gerard Michel serves as CEO. A veteran life sciences executive, Michel has led the company through its pivotal FDA approval and the subsequent U.S. commercial launch starting in early 2024.
Does Delcath Systems participate in fund commitments or direct deals?
No. Delcath is purely an operating company. It does not invest in funds, sponsor private equity deals, or co-invest alongside institutional allocators. Any capital the firm raises is deployed directly into its own R&D, clinical trials, and commercial operations.
Where is Delcath Systems' core market?
The United States is the primary market following the August 2023 FDA approval. The company also has a commercial presence in select European countries under a CE-marked version of its system.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: